Published in PLoS One on January 23, 2013
Metabolism and virulence in Neisseria meningitidis. Front Cell Infect Microbiol (2014) 0.98
New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res (2013) 0.96
Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of Neisseria meningitidis. J Bacteriol (2013) 0.89
Genome-Wide Assessment of Outer Membrane Vesicle Production in Escherichia coli. PLoS One (2015) 0.81
Outer membrane vesicles as platform vaccine technology. Biotechnol J (2015) 0.80
Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes. J Immunol Res (2015) 0.76
Interspecies Communication between Pathogens and Immune Cells via Bacterial Membrane Vesicles. Front Cell Dev Biol (2016) 0.75
The Hfq regulon of Neisseria meningitidis. FEBS Open Bio (2017) 0.75
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol (2006) 13.13
Nutritional profiles of Neisseria gonorrhoeae, Neisseria meningitidis, and Neisseria lactamica in chemically defined media and the use of growth requirements for gonococcal typing. J Infect Dis (1973) 12.22
Structure, function, and formation of biological iron-sulfur clusters. Annu Rev Biochem (2005) 6.82
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol (2010) 4.13
Relation between excreted lipopolysaccharide complexes and surface structures of a lysine-limited culture of Escherichia coli. J Bacteriol (1966) 3.36
Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann (1991) 3.32
Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev (2010) 3.27
Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response. Mol Microbiol (2006) 2.79
Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta (1976) 2.51
Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun (1972) 2.43
Micromolar intracellular hydrogen peroxide disrupts metabolism by damaging iron-sulfur enzymes. J Biol Chem (2006) 2.34
Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol (2004) 2.26
Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol (1979) 2.23
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol (2005) 2.17
Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun (2001) 2.16
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann (1991) 2.13
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine (2009) 1.88
The chemistry and electron microscopy of an extracellular lipopolysaccharide from Escherichia coli. Ann N Y Acad Sci (1966) 1.88
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Structure of the OmpA-like domain of RmpM from Neisseria meningitidis. Mol Microbiol (2004) 1.70
Biogenesis of bacterial membrane vesicles. Mol Microbiol (2009) 1.69
An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions. Biochem J (1965) 1.63
Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine (1995) 1.52
Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae. J Gen Microbiol (1967) 1.49
Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem (2005) 1.39
Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics (2006) 1.39
Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine (1996) 1.27
Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol (2004) 1.24
Transcriptome analysis of Neisseria meningitidis during infection. J Bacteriol (2003) 1.22
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol (2008) 1.22
Heat-induced blebbing and vesiculation of the outer membrane of Escherichia coli. J Bacteriol (1982) 1.21
Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis (2008) 1.19
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol (2006) 1.17
High yield production process for Shigella outer membrane particles. PLoS One (2012) 1.12
Fatal meningococcal septicaemia with "blebbing" meningococcus. Lancet (2002) 1.11
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine (2010) 1.09
Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol (2007) 1.08
Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine (2010) 1.08
Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun (2009) 1.07
Improved methods for producing outer membrane vesicles in Gram-negative bacteria. Res Microbiol (2004) 1.05
Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol (2010) 1.05
Analysis of the heat shock response of Neisseria meningitidis with cDNA- and oligonucleotide-based DNA microarrays. J Bacteriol (2002) 1.04
Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine (2005) 1.01
Effect of chelating agents on the susceptibility of some strains of gram-negative bacteria to some antibacterial agents. Antimicrob Agents Chemother (1974) 0.96
Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin (2011) 0.95
Effect of ethylenediaminetetraacetic acid and related chelating agents on whole cells of gram-negative bacteria. Antimicrob Agents Chemother (1974) 0.95
Escherichia coli FtnA acts as an iron buffer for re-assembly of iron-sulfur clusters in response to hydrogen peroxide stress. Biometals (2008) 0.93
Reactive oxygen species in normal physiology, cell injury and phagocytosis. Adv Exp Med Biol (1994) 0.93
Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines (2011) 0.92
Modeling Neisseria meningitidis B metabolism at different specific growth rates. Biotechnol Bioeng (2008) 0.85
Scale-up for bulk production of vaccine against meningococcal disease. Vaccine (2007) 0.84
Sulphur acquisition by Neisseria meningitidis. Can J Microbiol (1984) 0.82
Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine production. Biotechnol Bioeng (2009) 0.81
EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes. Acta Biochim Biophys Sin (Shanghai) (2007) 0.80
Expression of phosphofructokinase in Neisseria meningitidis. Microbiology (2009) 0.79
Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine (2012) 0.79
A Neisserial autotransporter NalP modulating the processing of other autotransporters. Mol Microbiol (2003) 1.56
The Omp85 protein of Neisseria meningitidis is required for lipid export to the outer membrane. EMBO J (2003) 1.23
Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues. J Biol Chem (2004) 1.22
Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis. Infect Immun (2008) 1.16
Crystal structure and catalytic mechanism of the LPS 3-O-deacylase PagL from Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2006) 1.15
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine (2010) 1.09
Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol (2007) 1.08
Naturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy. PLoS Pathog (2009) 1.08
Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell Microbiol (2006) 1.08
Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun (2006) 1.07
Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine (2011) 1.02
Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates. Carbohydr Res (2006) 1.01
Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine (2006) 1.00
Human dendritic cell activation by Neisseria meningitidis: phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production. Cell Microbiol (2004) 0.99
A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis. Microbes Infect (2006) 0.97
Expression of foreign LpxA acyltransferases in Neisseria meningitidis results in modified lipid A with reduced toxicity and retained adjuvant activity. Cell Microbiol (2002) 0.97
Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun (2007) 0.96
Mapping the binding domains on meningococcal Opa proteins for CEACAM1 and CEA receptors. Mol Microbiol (2003) 0.96
Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res (2004) 0.95
A novel secondary acyl chain in the lipopolysaccharide of Bordetella pertussis required for efficient infection of human macrophages. J Biol Chem (2007) 0.95
TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine (2007) 0.95
Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells. Infect Immun (2009) 0.94
Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS One (2010) 0.93
Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine (2013) 0.93
Conformational analysis of opacity proteins from Neisseria meningitidis. Eur J Biochem (2002) 0.88
Identification of a novel lipopolysaccharide core biosynthesis gene cluster in Bordetella pertussis, and influence of core structure and lipid A glucosamine substitution on endotoxic activity. Infect Immun (2009) 0.87
Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine (2011) 0.87
Involvement of lipooligosaccharides of Haemophilus influenzae and Neisseria meningitidis in defensin-enhanced bacterial adherence to epithelial cells. Microb Pathog (2003) 0.87
The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease. Infect Immun (2010) 0.87
Comparison of initial feasibility of host cell lines for viral vaccine production. J Virol Methods (2013) 0.86
Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form. Infect Immun (2003) 0.86
Biosynthetically engineered lipopolysaccharide as vaccine adjuvant. Expert Rev Vaccines (2015) 0.86
Mannose binding lectin enhances IL-1beta and IL-10 induction by non-lipopolysaccharide (LPS) components of Neisseria meningitidis. Cytokine (2004) 0.86
Neisseria meningitidis can induce pro-inflammatory cytokine production via pathways independent from CD14 and toll-like receptor 4. Eur Cytokine Netw (2003) 0.85
Assessment of mass transfer and mixing in rigid lab-scale disposable bioreactors at low power input levels. Biotechnol Prog (2014) 0.84
Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng (2010) 0.84
Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins. Vaccine (2004) 0.84
Scale-up for bulk production of vaccine against meningococcal disease. Vaccine (2007) 0.84
Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis. PLoS One (2013) 0.83
Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles. Vaccine (2013) 0.83
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine (2007) 0.83
PAT for vaccines: the first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease. Vaccine (2007) 0.83
Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. Clin Vaccine Immunol (2006) 0.82
Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity. Clin Vaccine Immunol (2010) 0.82
Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine (2007) 0.81
Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. J Proteome Res (2013) 0.81
LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A. Cell Microbiol (2013) 0.81
Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties. J Biol Chem (2014) 0.81
A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS. Vaccine (2007) 0.80
Association of chronic meningococcemia with infection by meningococci with underacylated lipopolysaccharide. J Infect (2011) 0.80
Scale-down of the inactivated polio vaccine production process. Biotechnol Bioeng (2012) 0.80
Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine. PLoS One (2012) 0.80
Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. Microbes Infect (2007) 0.79
Expression of phosphofructokinase in Neisseria meningitidis. Microbiology (2009) 0.79
Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine (2012) 0.79
Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses. Cell Microbiol (2012) 0.79
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease. Infect Immun (2005) 0.78
A cross-reactive neisserial antigen encoded by the NMB0035 locus shows high sequence conservation but variable surface accessibility. J Med Microbiol (2008) 0.78
Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria. J Lipid Res (2004) 0.78
Multi-antigen immunization using IgG binding domain ZZ as carrier. Vaccine (2005) 0.77
Physicochemical and immunochemical assays for monitoring consistent production of tetanus toxoid. Biologicals (2013) 0.77
Prevalence and clinical course in invasive infections with meningococcal endotoxin variants. PLoS One (2012) 0.77
Online automatic tuning and control for fed-batch cultivation. Bioprocess Biosyst Eng (2007) 0.75
Isoelectric point determination of live polioviruses by capillary isoelectric focusing with whole column imaging detection. Anal Chem (2013) 0.75
Scaling-up vaccine production: implementation aspects of a biomass growth observer and controller. Bioprocess Biosyst Eng (2008) 0.75
Phase variation of Opa proteins of Neisseria meningitidis and the effects of bacterial transformation. J Biosci (2016) 0.75
Evaluation of a critical process parameter: oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis. Biotechnol Bioeng (2009) 0.75